IL17A and inflammatory response: Our data confirm and extend previous studies showing that IL-17A targeting decreased kidney inflammation in preclinical models of renal damage, suggesting that the blockade of IL-17A could be an anti-inflammatory treatment to prevent hypertension-induced renal inflammation.